7-OH Kratom Is an Opioid. Most People Using It Don't Know That.

This article covers what is publicly known about 7-hydroxymitragynine as of June 2026. It draws on peer-reviewed pharmacology research, FDA regulatory actions, poison center data, and interviews conducted with ibogaine clinic staff for this site. It is not medical advice. If you or someone you love is struggling with substance use, please speak with a qualified healthcare provider.

The clinic director at New Path Ibogaine mentioned it almost in passing during our interview earlier this year. 7-OH kratom, he said, has become their most common presenting addiction in 2026. More common than fentanyl. More common than heroin or Suboxone.

A product sold at gas stations in most of the country as an herbal supplement.

I had heard variations on this from other clinics too. A pattern was forming. And the consistent detail underneath it was this: a significant portion of the patients arriving with 7-OH dependence did not know they were opioid-dependent. They knew they needed kratom every day to feel okay. They did not know that what they were taking was pharmacologically not meaningfully different from a prescription painkiller.

This piece is for them. And for their families.

What 7-OH actually is, and what it isn't

The first thing to understand is the distinction between kratom and 7-OH kratom, because the marketing collapses a distinction that pharmacology keeps separate.

Traditional kratom leaf, used for generations in Southeast Asia as an herbal stimulant and mild analgesic, contains mostly mitragynine as its primary alkaloid, making up roughly 40 to 60 percent of the alkaloid content. Mitragynine's pharmacology is complex and still being studied. What it is not, according to current research, is a potent opioid agonist. At the human mu-opioid receptor, the receptor that morphine, oxycodone, and fentanyl bind to, mitragynine appears to function more as an antagonist than a stimulant. Its effects involve other receptor systems, not primarily the opioid pathway.

7-hydroxymitragynine (7-OH) is different. It is also found in the kratom plant, but only in trace amounts, typically less than 2 percent of total alkaloid content. It is also produced in the body as a metabolite when you consume mitragynine. (So your body makes some 7-OH from regular kratom leaf. Just not in the concentrations these products deliver.)

The products at the gas station counter are not using the trace amounts found in kratom leaf. They are using concentrated, semi-synthetic extracts. Products tested by the Texas Department of State Health Services came back at concentrations up to 98 percent 7-OH. That is not an herbal product in any meaningful sense. That is something else, sold in packaging that says "kratom."

A 2021 study in the Journal of Pharmacological and Experimental Therapeutics confirmed what the pharmacological evidence had been pointing toward for years. 7-OH is a partial mu-opioid receptor agonist. Its discriminative stimulus effects in animal studies are fully substitutable with morphine and fentanyl. Analgesic potency estimates in animal models run up to 13 times that of morphine. And critically: naloxone reverses it. The opioid overdose antidote works because the opioid receptor is the mechanism.

"Potentially the fourth wave of the opioid epidemic." FDA Commissioner Martin Makary, July 2025

The FDA cited all of this when it issued warning letters to seven companies in July 2025 and formally recommended that the DEA place concentrated 7-OH in Schedule I.

Why the label says "kratom"

"Plant alkaloids." "Botanical extract." "Natural supplement." The product sits between the energy drinks and the protein powder. Nothing on the label reads opioid.

Kratom has been sold in the US for years as a legal, mildly stimulating herbal product loosely associated with Southeast Asian folk medicine. The concentrated 7-OH products borrow the name and the retail placement. What is in the bottle is something different.

The pharmacology does not support the positioning. There is no FDA-approved drug product containing 7-OH. These products cannot legally be sold as dietary supplements under the Dietary Supplement Health and Education Act of 1994, because 7-OH was synthesized in a lab in the 2010s and has no history as a food or supplement ingredient. The FDA's July 2025 warning letters noted exactly this, along with reports of adverse events including seizures, respiratory depression, liver toxicity, and deaths.

What this means practically: a person can walk into a gas station in most of the country, buy a product that looks like an energy shot, feel genuinely better from taking it, and over weeks or months develop a physical opioid dependence without ever having touched something a doctor would have called an opioid.

What withdrawal looks like

For someone who has been using concentrated 7-OH daily and tries to stop, the experience is opioid withdrawal. Published case reports document the clinical profile: severe muscle pain, nausea, vomiting, diarrhea, sweating, chills, anxiety, insomnia, intense cravings. Cases have been documented reaching moderate-to-severe on the Clinical Opiate Withdrawal Scale.

The timeline follows the short-acting opioid pattern. Symptoms typically begin within 12 hours of the last dose. They peak around 48 hours. The acute phase begins to improve by the end of the first week.

The part that surprises people is what comes after. Researchers at the University of Illinois at Chicago have noted that 7-OH withdrawal can produce a post-acute withdrawal syndrome lasting up to three months, with fatigue, mood instability, cognitive fog, and persistent cravings well past the acute phase. Standard 7-day detox programs may not be sufficient.

The 2025 poison control data reflects the severity. Washington State poison centers recorded roughly 1,800 kratom-related exposure calls in the first half of 2025, up from an annual average under 500 for the prior decade. Roughly a third involved concentrated 7-OH products. Pennsylvania documented 14 cases requiring mechanical ventilation. The LA County Medical Examiner confirmed three fatal overdoses in otherwise healthy adults aged 18 to 40, with 7-OH as the primary substance. The American College of Medical Toxicology published a sentinel case report concluding that 7-OH was the likely driver of an opioid toxidrome that ended in cardiac arrest.

Naloxone reverses it. Multiple confirmed cases. The opioid antidote works here because the opioid receptor is the mechanism. That is also the final piece of confirmation.

The drug test problem

Standard 5-panel, 10-panel, and 12-panel drug tests do not screen for kratom alkaloids. A person physically dependent on 7-OH will pass most standard workplace and clinical drug tests. Specialized testing can detect mitragynine in blood for roughly 12 days. Detecting 7-OH specifically requires specialty lab analysis that most standard settings do not offer.

For families trying to understand what is happening, this matters. "Clean drug test" is not informative here. The question to pay attention to is behavioral: Is the person uncomfortable, irritable, or sick when they don't have their kratom? Do they use more than they intend to? Have they tried to stop? That is what dependence looks like, and it looks the same whether the substance is heroin or something sold as an herbal supplement.

The ibogaine treatment dimension

If ibogaine treatment is part of the picture, here is what the 7-OH history actually changes.

Ibogaine carries cardiac risk. It prolongs the QT interval on an EKG, which creates arrhythmia risk in patients whose cardiac baseline is not well managed. The protocol at legitimate clinics involves EKG screening, electrolyte optimization, and a transition from long-acting opioids to short-acting opioids before the flood dose. The whole architecture of pre-treatment is designed around knowing exactly what is in the patient's system, and what their heart is doing.

7-OH complicates all three of these.

First, the pharmacokinetics of concentrated commercial 7-OH products are not well characterized. How long the compound stays in the system, and at what concentrations, depends on the product, the dose, and the individual. Clinics cannot rely on standard opioid conversion tables, because the products vary dramatically in concentration. This means more conservative timelines to confirm clearance before proceeding.

Second, there is a cardiac overlap. Kratom alkaloids inhibit the same cardiac ion channel that ibogaine blocks, the hERG potassium channel, which governs the QT interval. A published JACC Case Reports case from 2025 documented reversible QTc prolongation in a patient using kratom, independent of ibogaine. A patient arriving with recent 7-OH use may already have subclinical QTc prolongation. Adding ibogaine to an already-elevated QTc baseline is the scenario that ibogaine clinic safety protocols are specifically designed to prevent.

Third, the stabilization period for 7-OH patients tends to be longer than for heroin or fentanyl patients. Clinics experienced with this population describe extended pre-treatment to ensure alkaloid clearance, allow cardiac normalization, and establish stable short-acting opioid dosing before the ibogaine session begins.

None of this makes ibogaine treatment unavailable to someone coming from 7-OH dependence. The preparation is manageable. Several clinics in the directory on this site have treated 7-OH patients. What makes the preparation unmanageable is information the clinic does not have. Concealing or understating 7-OH use from a clinic is the scenario where harm risk increases.

What families need to know

The label says kratom. The pharmacology says opioid. If the product is a tablet, gummy, shot, or liquid extract rather than raw dried leaf, and it is concentrated, the active compound may be 7-OH. Not traditional kratom. Pharmacologically, a different thing.

Standard drug tests will not catch it. If a family member is using concentrated kratom products heavily and showing withdrawal symptoms when they stop, that is opioid dependence, even if the drug test is clean.

Naloxone works. Carry it. Multiple confirmed cases have shown that naloxone reverses 7-OH toxicity. Because most people, and many first responders, do not associate kratom products with opioid overdose, it may not be deployed when it should be. If someone in your household uses concentrated 7-OH products, having naloxone available is reasonable harm reduction.

Withdrawal is severe and longer than most people expect. The acute phase resolves over days. Post-acute symptoms, including mood instability, fatigue, and cravings, can persist for months. Standard short detox programs may not be enough.

Ibogaine treatment is possible, but requires full disclosure. The cardiac overlap between 7-OH and ibogaine means clinics need accurate information to design safe protocols. What they don't know about, they can't protect against.

The legal landscape is moving, but slowly. As of June 2026, concentrated 7-OH has been banned in Florida, Louisiana, Mississippi, Colorado, California, and several other states. The FDA has formally asked the DEA to schedule it. Full scheduling could take another 18 to 24 months. In most of the country, it is still available legally. Legal does not mean safe.

Map

Where 7-OH kratom is banned

As of June 2026. Hover any state for details.

Legal (no statewide ban)

Banned or restricted

Enforcement action

Most of the people I have spoken with who ended up at an ibogaine clinic coming off 7-OH describe a version of the same arc. They were not, in their own telling, addicts. They had found something that helped. It was legal. It was at the counter by the register. By the time they understood what they were dealing with, they had been dealing with it for a year.

This site has covered SR17018, a research compound being sold direct-to-consumer as a potential bridge for 7-OH withdrawal, in a separate piece. If you encounter it while researching treatment options, the overview there explains what the compound is, what is known about it, and what is not.